Sign in
CompletedPhase 4

Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance

Key facts

Who runs it
Azienda Ospedaliero, Universitaria Pisana
Where
Italy7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
104 people enrolled
Started
3 Aug 2020
Ended
17 Jul 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Group 1, CMR-guided/aided VT ablation
  • Group 2, CMR-aided VT ablation
  • Group 3, Electroanatomical guided ablation
Record updated
15 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Indication for VT ablation in patients with SHD (indications according to the 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death)
  • Structural heart disease (clinical history, EKG, multimodality imaging)
  • Signed informed consent

Who cannot take part

  • Acute coronary syndrome in the previous 3 months
  • Heart surgery for valve disease in the previous 6 months or expected within 6 months,
  • Previous VT ablation (redo procedure)
  • Severe chronic liver disease (Child-Pugh score C) (according to clinical history or out/in-patient tests performed upon enrollment)
  • NYHA functional class IV heart failure or CCS functional class IV angina
  • Systemic illness likely to limit survival to < 1 year
  • Creatinine clearance < 15 ml/min (stage 5 CKD) (according to clinical history or out/in-patient tests performed upon enrollment)
  • Age <18 y
  • ICD not already implanted nor expected within 1 month
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
  • Inability to give written informed consent
  • Pregnancy (suspected or confirmed)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Previous monocentric experiences have already highlighted the role of preoperative cardiac imaging, in particular of cardiac magnetic resonance (CMR) and tomography (CT), in improving the ablation results of scar-related ventricular tachycardia (VT). A better characterization of scar obtained with high quality CMR images and post processing data with creation of maps exploring the heart in concentric layers from the endocardium to the epicardium could allow a personalized and more precise approach to this pathology.

Read full original descriptionShow less

Aim of the study - Evaluating the feasibility and possible benefit of CMR-guided ablative approach (group 1: ablation of the "anatomical" channels of heterogeneous tissue within the scar) compared to CMR-aided approach (group 2: ablation of the "electrical" conduction channels within the scar) and standard approach (group 3: ablation guided by an electro-anatomical system without the aid of CMR) in a multi-center Tuscan study.

What would add the project to what is known - The achievement of the objectives by the project would allow to propose a personalized ablation on the basis of the scar characterization and would allow a better efficacy, efficiency of the procedure and probably also a safer treatment

The 3 groups in the trial

  • Group 1, CMR-guided VT ablationTreatment being tested

    Patients randomized to Group 1, will undergo CMR-guided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain). Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.

    Treatment: Group 1, CMR-guided/aided VT ablation

  • Group 2, CMR-aided VT ablationTreatment being tested

    Patients randomized to Group 2, will undergo CMR-aided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain). Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.

  • Group 3, Electroanatomical guided ablationExisting treatment, for comparison

    Patients assigned to Group 3, will not undergo LGE-CMR. Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
VOYAGE- Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance
Publications
Record updated
15 December 2025